medigraphic.com

2016, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (6)

Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma

Gopar-Nieto R, Cabello-López A, Juárez-Pérez CA, Haro-García LC, Jiménez-Ramírez C, Aguilar-Madrid G

Language: Spanish
References: 35
Page: 770-776
PDF size: 300.61 Kb.


ABSTRACT

Malignant pleural mesothelioma is an occupational tumor caused by asbestos exposure. In Mexico, as asbestos usage is not prohibited, an increase in the number of cases is expected. Asbestos exposure is ubiquitous due to the great amount of products in which it is present. Its carcinogenicity is caused as the inhaled asbestos fibers cannot be eliminated by macrophages and, thus, they travel to the pleura through lymphatic pathways, producing a persistent inflammatory response. Diagnosis approach includes occupational history, along with clinical signs and symptoms, and paraclinical studies, such as pleural fluid cytology, chest x-rays, computed tomography, magnetic resonance imaging, and biopsy with immunohistochemistry. The main differential diagnosis is lung adenocarcinoma. Regarding the treatment of this tumor, it mainly comprises palliative care, even though chemotherapy, radiotherapy, and, in selected cases, surgical treatments have been used. There is an urgent need for general physicians and specialists to identify asbestos exposure, in order to make a timely diagnosis. Research is necessary to develop screening and prompt diagnostic tools, along with an epidemiological surveillance program for the workers and the general population exposed to asbestos.


REFERENCES

  1. Selikoff IJ, Hammond EC, Churg J. Mortality experience of insulation workers in the United States and Canada, 1943-1968. In: Shapiro HA. Pneumoconiosis. Proceeding of the International Conference. Johannesburg, Cape Town, South Africa: Oxford University Press;1969. pp. 180-186.

  2. Selikoff IJ, Hammond EC, Churg J. Asbestos exposure and neoplasia. JAMA.1964;188:22-6.

  3. Selikoff IJ. Mortality experience of insulation workers in the United States and Canada, 1943-1947. Ann NY Acad Sci. 1979;330:91-116.

  4. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risk to humans. Vol. 14. Lyon, France: IARC: 1977.

  5. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Suppl. 7. Lyon, France: IARC;1987. pp. 106-116.

  6. Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff J. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis and causes of death. Br J Ind Med.1988;45:182-7.

  7. Ray M, Kindler HL. Malignant Pleural Mesothelioma: An update on biomarkers and treatment. Chest. 2009;136:888-96.

  8. Aguilar-Madrid G, Juárez-Pérez C, Markowitz S, Hernández-Ávila M, Sánchez Román F, Vázquez Grameix J. Globalization and the transfer of hazardous industry: Asbestos in Mexico, 1979-2000. Int J Occup Environ Health. 2003;9:272-9.

  9. Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA, Alvarado- Cabrero I, Rico-Méndez FG, Kelly-García J. Casecontrol study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med. 2010;53:241-51.

  10. Benamore RE, O'Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol. 2005;60:1237-47.

  11. Van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: The standard of care and challenges for the future. Crit Rev Oncol Hematol. 2011;78:92-111.

  12. Hasegawa S. Early mesothelioma revisited. Int J Clin Oncol. 2012;17:30-2.

  13. Hasegawa S, Tanaka F. Malignant mesothelioma: current status and perspective in Japan and in the world. Gen Thorac Cardiovasc Surg. 2008;56:317-23.

  14. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax.1999;54(7):638-52.

  15. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant Mesothelioma: Facts, Myths and Hypotheses. J Cell Physiol. 2011;227:44-58.

  16. Fuhrer G, Lazarus AA. Mesothelioma. Dis Mon. 2011;57(1):40-54.

  17. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-72.

  18. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetic of bone and soft tissue tumor. Mesothelioma. Cancer Genet Cytogenet. 2001;127(2):93-110.

  19. Goparaju CM, Blasberg JD, Volinia S, Palatini J, Ivanov S, Donington JS, et al. Onconase mediated NFKb downregulation in malignant pleural Mesothelioma. Oncogene. 2011;30(24):2767-77.

  20. Dou J, Yu S, Bian C. [Clinical analysis of 19 patients with pleural mesothelioma]. Zhonghua Zhong Liu Za Zhi. 1998;20(5):387-8.

  21. Rusch VW. Clinical features and current treatment of diffuse malignant pleural mesothelioma. Lung Cancer. 1995;12(S2):S127-46.

  22. Cardinale L, Ardissone F, Asteggiano F, Laugelli EM, Penna D, Fava C. Diffuse neoplasms of the pleural serosa. Radiol Med. 2012;118(3):366-78.

  23. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer. 2004;45(S1):S73-6.

  24. Husain A, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley M, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 Update of the consensus statement fromt the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2012;136:1-21.

  25. Zhou H, Tamura T, Kusaka Y, Suganuma N, Subhannachart P, Vijitsanguan C, et al. Development of a guideline on reading CT images of malignant pleural mesothelioma and selection of the reference CT films. Eur J Radiol. 2012; 81(12):4203-10.

  26. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64:356-66.

  27. Metintas M, Ucgun I, Elbek O, Erginel S, Metintas S, Kolsuz M, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol. 2002;41:1-9.

  28. Gopar-Nieto R, Aguilar-Madrid G, Sotelo-Martínez L, Juárez-Pérez CA, Kelly-García J, Argote-Greene L, et al. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population. Arch Med Res. 2015;46:107-11.

  29. Zhou H, Tamura T, Kusaka Y, Suganuma N, Subhannachart P, Vijitsanguan, et al. Evaluation of the efficacy of the guideline on reading CT images of malignant pleural mesothelioma with reference CT films for improving the proficiency of radiologists. Eur J Radiol. 2012;82(1)169-76.

  30. Fiore D, Baggio V, Sotti G, Muzzio PC. Imaging before and after multimodal treatment for malignant pleural mesothelioma. Radiol Med. 2006;111:355-64.

  31. Dimarakis I, Rehman S, Machaal A, Shah R. PET-CT in the diagnosis of localized malignant pleural mesothelioma. Clin Imaging. 2011;35(6):476-7.

  32. Van Thiel E, van Meerbeeck JP. European guidelines for the management of malignant pleural mesothelioma. Pol Arch Med Wewn. 2010;120(12):503-10.

  33. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.

  34. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2): 257-60.

  35. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer. 2005;49(S1):S37-40.




2020     |     www.medigraphic.com